Clinical Experience of Sirolimus Regarding Efficacy and Safety in Systemic Lupus Erythematosus
New treatment options constitute unmet needs for patients diagnosed with systemic lupus erythematosus (SLE). Inhibition of the mammalian target of rapamycin (mTOR) pathway by sirolimus, a drug approved and in clinical use to prevent transplant rejection, has shown promising effects in lupus animal m...
| Main Authors: | , , |
|---|---|
| פורמט: | Article |
| שפה: | English |
| יצא לאור: |
Frontiers Media S.A.
2019-02-01
|
| סדרה: | Frontiers in Pharmacology |
| נושאים: | |
| גישה מקוונת: | https://www.frontiersin.org/article/10.3389/fphar.2019.00082/full |